Federal Register / Vol. 89, No. 5 / Monday, January 8, 2024 / Notices 929 

Contact Person: Anita Szajek, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development, National Institutes of Health, 

6701 Rockledge Drive, Room 2131D, 

Bethesda, MD 20892, anita.szajek@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.865, Research for Mothers 

and Children, National Institutes of Health, 

HHS) 

Dated: January 3, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00115 Filed 1–5–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development; Notice of Closed 

Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Biobehavioral and 

Behavioral Sciences Study Section. 

Date: March 19, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Eunice 

Kennedy Shriver National Institute of Child 

Health and Human Development, 6710B 

Rockledge Drive, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Chi-Tso Chiu, Ph.D., 

Scientific Review Branch (SRB), Eunice 

Kennedy Shriver National Institute of Child 

Health & Human Development, NIH, DHHS, 

6710B Rockledge Drive, Rm. 2127B, 

Bethesda, MD 20817, (301) 435–7486, chiuc@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: January 3, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00113 Filed 1–5–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development; Notice of Closed 

Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Eunice Kennedy 

Shriver National Institute of Child Health 

and Human Development Initial Review 

Group; Obstetrics and Maternal-Fetal Biology 

Study Section. 

Date: March 22, 2024. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Eunice 

Kennedy Shriver National Institute of Child 

Health and Human Development, 6710B 

Rockledge Drive, Room 2131B, Bethesda, MD 

20892 (Virtual Meeting). 

Contact Person: Luis E. Dettin, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development, National Institutes of Health, 

6710B Rockledge Drive, Room 2131B, 

Bethesda, MD 20892, (301) 827–8231, 

luis.dettin@nih.gov. 

Name of Committee: Eunice Kennedy 

Shriver National Institute of Child Health 

and Human Development Initial Review 

Group; Function, Integration, and 

Rehabilitation Sciences Study Section. 

Date: April 8–9, 2024. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Eunice 

Kennedy Shriver National Institute of Child 

Health and Human Development, 6710B 

Rockledge Drive, Room 2125D, Bethesda, MD 

20892 (Virtual Meeting). 

Contact Person: Moushumi Paul, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development, National Institutes of Health, 

6710B Rockledge Drive, Room 2125D, 

Bethesda, MD 20817, (301) 496–3596, 

moushumi.paul@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.865, Research for Mothers 

and Children, National Institutes of Health, 

HHS) 

Dated: January 3, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00114 Filed 1–5–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Terrence Joyce at (240) 987–2347, or 

Terrence.joyce@NIH.gov. Licensing 

information may be obtained by 

communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852: tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Vesicular Stomatitis Virus (VSV)-Based 

Vaccine Against Sudan Virus 

Description of Technology: 

There are five known Ebolavirus 

species: Ebola virus (Zaire ebolavirus); 

Sudan virus (Sudan ebolavirus or 

SUDV); Taı ̈ Forest virus (Taı ̈ Forest 

ebolavirus, formerly Cote d’Ivoire 

ebolavirus); Bundibugyo virus 

(Bundibugyo ebolavirus); and Reston 

virus (Reston ebolavirus). Last year an 

ebolavirus outbreak resulted in 164 

cases and 55 deaths. While there is an 


ddrumheller on DSK120RN23PROD with NOTICES1
930 Federal Register / Vol. 89, No. 5 / Monday, January 8, 2024 / Notices 

FDA-approved Ebola virus vaccine 

authorized for use against Ebola virus 

infections, ERVEBO, this vaccine is not 

effective against SUDV due to the 

significant variation between Ebola 

virus and SUDV. ERVEBO is a live 

recombinant viral vaccine consisting of 

a vesicular stomatitis virus (VSV) 

backbone deleted for the VSV envelope 

glycoprotein and substituted with the 

envelope glycoprotein of the Ebola virus 

(Kikwit 1995 strain). 

This invention provides a VSV-based 

vaccine expressing the SUDV-Gulu GP 

(VSV–SUDV). The VSV backbone of this 

vaccine appears to be very similar to the 

VSV backbone used in the ERVEBO 

vaccine discussed above. This could 

allow for a quicker and more efficient 

regulatory approval pathway through 

the FDA. Efficacy studies in non-human 

primates demonstrated that a single 

intramuscular vaccination protected 

animals from a lethal challenge dose of 

SUDV even when vaccination occurred 

only seven days prior to challenge. In 

addition, pre-exposure to the VSV 

vector did not inhibit a robust response 

to the SUDV GP component of the 

vaccine. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications: 

• Prophylactic usage against SUDV 

infections in normal or high-risk 

populations. 

• Therapeutic treatment, alone or in 

combination, in patients with SUDV 

infection. 

• Assay development for 

surveillance, diagnostic, and prevention 

measures. 

Competitive Advantages: 

• Uses a VSV-based system to express 

antigens thereby increasing safety of the 

vaccine. 

• Efficacious after single low dose 

vaccination in NHPs. 

• VSV-platform induces a strong & 

rapid immune response. 

Development Stage: Pre-clinical. 

Inventors: Andrea Marzi, Ph.D., and 

Heinz Feldmann, MD, Ph.D., both of 

NIAID. 

Publications: Marzi, A, et al., 

‘‘Species-specific immunogenicity and 

protective efficacy of a vesicular 

stomatitis virus-based Sudan virus 

vaccine: a challenge study in 

macaques,’’ Lancet Microbe, 2023 

Mar;4(3): e171-e178. doi: 10.1016/ 

S2666–5247(23)00001–0. Epub 2023 Feb 

2. 

Intellectual Property: U.S. Provisional 

Application No. 63/419,637, filed 

October 26, 2022, U.S. Provisional 

Application No. 63/517,246 filed 

August 02, 2023, and PCT application 

PCT/US2023/077444 filed on October 

20, 2023. 

Licensing Contact: To license this 

technology, please contact Dr. Terrence 

Joyce at (240) 987–2347, or 

Terrence.joyce@NIH.gov, and reference 

E–002–2023. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. For 

collaboration opportunities, please 

contact Dr. Terrence Joyce at (240) 987– 

2347, or Terrence.joyce@NIH.gov. 

Dated: January 2, 2024. 

Haiqing Li, 

Acting Deputy Director, Technology Transfer 

and Intellectual Property Office, National 

Institute of Allergy and Infectious Diseases. 

[FR Doc. 2024–00087 Filed 1–5–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development; Notice of Closed 

Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Eunice Kennedy 

Shriver National Institute of Child Health 

and Human Development Initial Review 

Group; Reproduction, Andrology, and 

Gynecology Study Section. 

Date: February 15, 2024. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Eunice 

Kennedy Shriver National Institute of Child 

Health and Human Development, 6710B 

Rockledge Drive, Room 2125D, Bethesda, MD 

20892 (Virtual Meeting). 

Contact Person: Jagpreet Singh Nanda, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development, National Institutes of 

Health, 6710B Rockledge Drive, Room 2125D, 

Bethesda, MD 20892, (301) 451–4454, 

jagpreet.nanda@nih.gov. 

Name of Committee: Eunice Kennedy 

Shriver National Institute of Child Health 

and Human Development, Initial Review 

Group; Developmental Biology Study 

Section. 

Date: February 23, 2024. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Eunice 

Kennedy Shriver National Institute of Child 

Health and Human Development, 6710B 

Rockledge Drive, Room 2131B, Bethesda, MD 

20892 (Virtual Meeting). 

Contact Person: Jolanta Maria Topczewska, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development, National Institutes of 

Health, 6710B Rockledge Drive, Room 2131B, 

Bethesda, MD 20892, (301) 451–0000, 

jolanta.topczewska@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.865, Research for Mothers 

and Children, National Institutes of Health, 

HHS) 

Dated: January 3, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00112 Filed 1–5–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–2023–0586] 

National Commercial Fishing Safety 

Advisory Committee; September 2023 

Meetings 

AGENCY: United States Coast Guard, 

Department of Homeland Security. 

ACTION: Notice of availability of 

recommendations and request for 

comments. 

SUMMARY: The U. S. Coast Guard 

announces the availability of 

recommendations from the National 

Commercial Fishing Safety Advisory 

Committee (NCFSAC). The Committee 

met in September 2023 and sent eight 

recommendations to the Secretary of 

Homeland Security. The U.S. Coast 

Guard issues this Notice as the 

mechanism for receiving public 

comments and requests public 

comments on the recommendations. 

DATES: Comments must be submitted on 

or before April 8, 2024. 


ddrumheller on DSK120RN23PROD with NOTICES1